These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10528328)

  • 1. [Recent advances in Parkinson disease].
    Litvan I
    Rev Neurol; 1999 Jul 16-31; 29(2):139-45. PubMed ID: 10528328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for the treatment of Parkinson's disease.
    LeWitt PA
    Pharmacotherapy; 2000 Jan; 20(1 Pt 2):26S-32S. PubMed ID: 10641989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
    Widnell KL; Comella C
    Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [COMT inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553
    [No Abstract]   [Full Text] [Related]  

  • 12. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical issues with COMT inhibitors in Parkinson's disease.
    Waters C
    Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
    Waters C
    J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC; Adler CH
    Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 17. COMT inhibition in Parkinson's disease: rationale and clinical relevance.
    Deleu D
    Acta Neurol Belg; 2000 Mar; 100(1):5-7. PubMed ID: 10779856
    [No Abstract]   [Full Text] [Related]  

  • 18. Several classes of new drugs emerging for Parkinson disease.
    Phillips P
    JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
    [No Abstract]   [Full Text] [Related]  

  • 19. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
    Schapira AH; Obeso JA; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.